tradingkey.logo

BRIEF-Pfizer Confident That Its COVID-19 Portfolio Will Continue To Be Predictable & Durable Contributor

ReutersFeb 4, 2025 12:30 PM

- Pfizer Inc PFE.N:

  • PFIZER: EXPECT HIGHER GROSS-TO-NET IMPACT ON OUR REVENUES FOR ALL DRUGS IN THE BEGINNING OF 2025 WHEN COMPARED TO 2024 - PREPARED REMARKS

  • PFIZER: EXPECT HIGHER GROSS-TO-NET IMPACT ON REVENUES FOR ALL DRUGS TO MODERATE THROUGH REMAINDER OF 2025, WHEN COMPARED TO 2024

  • PFIZER SAYS BELIEVE OUR REVENUE VOLATILITY IS LARGELY IN THE PAST AS COVID- RELATED UNCERTAINTIES HAVE DIMINISHED

  • PFIZER: CONTINUE TO SEE STABILIZING PATTERNS IN DISEASE BURDEN WITH STRONG CORRELATION BETWEEN COVID-19 BURDEN OF DISEASE AND PAXLOVID UTILIZATION

  • PFIZER SEES THE SAME STABILIZING PATTERNS IN U.S. VACCINATION RATES AT RELATIVELY LOW LEVELS

  • PFIZER: CONFIDENT THAT OUR COVID-19 PORTFOLIO WILL CONTINUE TO BE A PREDICTABLE AND DURABLE CONTRIBUTOR TO OUR BUSINESS

  • PFIZER: INTEND TO MONETIZE OUR REMAINING HALEON INVESTMENT IN A "PRUDENT FASHION" DURING 2025

  • PFIZER: CONTINUE TO EVALUATE OTHER STRATEGIES TO IMPROVE OUR NETWORK STRUCTURE AND PRODUCT PORTFOLIO

  • PFIZER: ACHIEVED MARKET LEADERSHIP POSITION FOR SEASON IN SHIPPED DOSES FOR ABRYSVO, WITH ABOUT 13 PERCENTAGE POINT INCREASE IN MARKET SHARE

Source text: [ID:]

Further company coverage: PFE.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI